Lauren Bassaro1, Stephen J Russell1, Elzbieta Pastwa1, Stella A Somiari2, Richard I Somiari3. 1. Functional Genomics & Proteomics Unit, ITSI-Biosciences, Johnstown, PA, U.S.A. 2. Biobanking & Biospecimen Science Research Unit, Windber Research Institute, Windber, PA, U.S.A. 3. Functional Genomics & Proteomics Unit, ITSI-Biosciences, Johnstown, PA, U.S.A. Richard@itsi.us.
Abstract
BACKGROUND/AIM: Autoantibodies have potential as circulating biomarkers for early cancer detection. This study aimed to screen for known autoantibodies in human plasma using an Autoantibody Profiling System (APS) and quantify the levels in plasma of donors with/without breast cancer. MATERIALS AND METHODS: Plasma from nine female donors diagnosed with breast cancer (test group) and nine matched donors with no personal history of cancer (reference group) were screened with an APS containing probes for 30 autoantibodies. Autoantibody levels ≥1.5 times the mean concentration of the group were considered elevated, and test/reference ratios ≥1.3 were considered higher in the test group compared to the reference group. RESULTS: Twenty percent of the probes detected elevated levels of autoantibodies against proteins involved in different cancer mechanisms. Amongst these, the levels of autoantibodies against interleukin 29 (IL29), osteoprotegerin (OPG), survivin (SUR), growth hormone (GRH) and resistin (RES) were significantly higher in the cancer group compared to the reference group (p<0.05), whereas the level of autoantibody against cytotoxic T-lymphocyte associated antigen-4 (CTLA4) was not significantly different between the two groups (p=0.38). CONCLUSION: Disease-relevant autoantibodies were detected in the plasma of patients with breast cancer and donors without breast cancer. This means that identifying the type and level of autoantibodies in samples will be important in determining their significance in the disease process. A microtiter plate-based array system could be a fast and inexpensive screening method for identifying and quantifying autoantibodies in human plasma. Copyright
BACKGROUND/AIM: Autoantibodies have potential as circulating biomarkers for early cancer detection. This study aimed to screen for known autoantibodies in human plasma using an Autoantibody Profiling System (APS) and quantify the levels in plasma of donors with/without breast cancer. MATERIALS AND METHODS: Plasma from nine female donors diagnosed with breast cancer (test group) and nine matched donors with no personal history of cancer (reference group) were screened with an APS containing probes for 30 autoantibodies. Autoantibody levels ≥1.5 times the mean concentration of the group were considered elevated, and test/reference ratios ≥1.3 were considered higher in the test group compared to the reference group. RESULTS: Twenty percent of the probes detected elevated levels of autoantibodies against proteins involved in different cancer mechanisms. Amongst these, the levels of autoantibodies against interleukin 29 (IL29), osteoprotegerin (OPG), survivin (SUR), growth hormone (GRH) and resistin (RES) were significantly higher in the cancer group compared to the reference group (p<0.05), whereas the level of autoantibody against cytotoxic T-lymphocyte associated antigen-4 (CTLA4) was not significantly different between the two groups (p=0.38). CONCLUSION: Disease-relevant autoantibodies were detected in the plasma of patients with breast cancer and donors without breast cancer. This means that identifying the type and level of autoantibodies in samples will be important in determining their significance in the disease process. A microtiter plate-based array system could be a fast and inexpensive screening method for identifying and quantifying autoantibodies in human plasma. Copyright
Authors: Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: Simon S Cross; Zhiyong Yang; Nicola J Brown; Sabapathy P Balasubramanian; Clair A Evans; Julia K Woodward; Helen L Neville-Webbe; Jenny M Lippitt; Malcolm W R Reed; Robert E Coleman; Ingunn Holen Journal: Int J Cancer Date: 2006-04-15 Impact factor: 7.396
Authors: Jo K Perry; Kumarasamypet M Mohankumar; B Starling Emerald; Hichem C Mertani; Peter E Lobie Journal: J Mammary Gland Biol Neoplasia Date: 2008-02-07 Impact factor: 2.673
Authors: Luhui Shen; Zhan-Gong Zhao; John C Lainson; Justin R Brown; Kathryn F Sykes; Stephen Albert Johnston; Chris W Diehnelt Journal: RSC Adv Date: 2020-08-11 Impact factor: 4.036